Genta/Aventis Genasense Rolling NDA Submission Will Be Completed In Q4
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genta’s Phase III Genasense results should be enough to gain FDA approval for treatment of malignant melanoma despite the lack of a statistically significant improvement in survival in the intent to treat population, the firm told a Sept. 10 conference call.
You may also be interested in...
Year-End Submissions Total 17, Including Four From Aventis
Aventis was the most prominent participant in the year-end NDA filing rush, submitting four applications: two new molecular entities, a vaccine and a new formulation.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product